Search Results

ILiAD Biotechnologies, LLC (ILiAD) reported today that BPZE1, the most advanced next generation pertussis vaccine, demonstrated positive topline interim results in the SUPER (Stand Up to Pertussis) school-age trial conducted in 366 participants in the United Kingdom, Australia and Costa Rica.

ILiAD Biotechnologies, LLC today announced the selection of Emmes Group, a global contract research and technology organization, to conduct upcoming Phase III studies of its lead pertussis vaccine candidate, BPZE1. ILiAD and Emmes Group are currently working to finalize the definitive agreement.

ILiAD Biotechnologies, LLC (ILiAD), a vaccine company utilizing its B-Tech technology to develop novel vaccines against infectious diseases, today announced Chief Medical Officer Stephanie Noviello, MD, MPH, will present data on its pertussis vaccine, BPZE1, at the World Vaccine Congress Europe in Barcelona, Spain (October 17 – 19, 2023).

ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most advanced next generation pertussis vaccine announces positive primary data outcomes in the CHAMPION-1 clinical trial conducted at University Hospital Southampton (UK) and University of Oxford (UK).

ILiAD Biotechnologies, LLC (ILiAD), a vaccine company utilizing its B-Tech™ technology to develop novel vaccines against infectious diseases, today announced that Chief Medical Officer Stephanie Noviello, MD, MPH, will present information regarding its pertussis vaccine, BPZE1, at the World Vaccine Congress in Washington, DC (April 3 – 6, 2023).

ILiAD Biotechnologies, LLC (ILiAD), a vaccine company utilizing its B-Tech technology to develop novel vaccines against infectious diseases, today announced a peer-reviewed publication in The Lancet.